GA101 (obinutuzumab) monocLonal Antibody as Consolidation Therapy In CLL (GALACTIC) trial: study protocol for a phase II/III randomised controlled trial-Reference-Cited by-同舟云学术

GA101 (obinutuzumab) monocLonal Antibody as Consolidation Therapy In CLL (GALACTIC) trial: study protocol for a phase II/III randomised controlled trial

Published:2017-07-26 Issue:1 Volume:18 Page:
ISSN:1745-6215
Container-title:Trials
language:en
Short-container-title:Trials

Author:

Oughton Jamie B.,Collett Laura,Howard Dena R.,Hockaday Anna,Munir Talha,McMahon Kathryn,McParland Lucy,Dimbleby Claire,Phillips David,Rawstron Andy C.,Hillmen Peter

Funder

Cancer Research UK

Roche

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Medicine (miscellaneous)

Link

http://link.springer.com/content/pdf/10.1186/s13063-017-2107-0.pdf

Reference16 articles.

1. Fischer K, Cramer P, Busch R, Stilgenbauer S, Bahlo J, Schweighofer CD, et al. Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol. 2011;29(26):3559–66.

2. Hillmen P. Chronic lymphocytic leukaemia—moving towards cure? Lancet. 2010;376(9747):1122–4.